On this episode, I speak with Nick Lynch of the Pistoia Alliance ( www.pistoiaalliance.org ), a global nonprofit community of life science stakeholders that works to lower barriers to R&D innovation. A new area of strategic focus is artificial intelligence, which Nick oversees. On this episode, you'll learn challenges with AI that the Pistoia Alliance aims to address, why education and data are key to doing so, and how you can get involved.

This episode is brought to you by BenchSci ( www.benchsci.com ). BenchSci uses artificial intelligence to reduce the time, uncertainty, and cost of scientific experiments. Use it to find research antibodies up to 24x faster than using PubMed or Google Scholar. Just enter a protein of interest and filter by technique, organism, tissue, or 13 other options. BenchSci returns only relevant published figures and products. It’s free for academic researchers. Learn more and sign up at www.benchsci.com .

Nick Lynch of the Pistoia Alliance on AI as a Strategic Focus

Get knowledge and inspiration to apply artificial intelligence to drug development. Discover startups applying machine learning to biomedical research. Hear how biotech and pharma companies use AI to speed discovery and cut costs. Learn from academic researchers pushing boundaries in applying computation to biology. We interview leaders transforming drug development with data and algorithms. Subscribe now and never miss an episode!

Technology

Tech News

Podcasting

Gadgets

Software How-To

On this episode, I speak with Lucas Siow, Head of Business Operations at ProteinQure ( www.proteinqure.com ). ProteinQure uses artificial intelligence and quantum computing to design protein-based drugs such as antibodies and peptides. On this episode, you'll learn the benefits of protein-based drugs, challenges with discovering them, and how ProteinQure has combined emerging technologies in what may be the most science fiction-sounding drug discovery startup I've seen yet.

This episode is brought to you by BenchSci ( www.benchsci.com ). BenchSci uses artificial intelligence to reduce the time, uncertainty, and cost of scientific experiments. Use it to find research antibodies up to 24x faster than using PubMed or Google Scholar. Just enter a protein of interest and filter by technique, organism, tissue, or 13 other options. BenchSci returns only relevant published figures and products. It’s free for academic researchers. Learn more and sign up at www.benchsci.com .

Lucas Siow of ProteinQure on AI for Protein-Based Drugs

On this episode, I speak with Regina Barzilay of MIT's Machine Learning for Pharmaceutical Discovery and Synthesis consortium ( http://mlpds.mit.edu ). Regina is a prolific researcher with many highly cited papers in machine learning. On this episode, you'll learn what drove the need for the consortium, the importance of standards and benchmarks for AI drug discovery research, and the progress researchers are making in applying machine learning to chemical synthesis.

This episode is brought to you by BenchSci ( www.benchsci.com ). BenchSci uses artificial intelligence to reduce the time, uncertainty, and cost of scientific experiments. Use it to find research antibodies up to 24x faster than using PubMed or Google Scholar. Just enter a protein of interest and filter by technique, organism, tissue, or 13 other options. BenchSci returns only relevant published figures and products. It’s free for academic researchers. Learn more and sign up at www.benchsci.com .

Regina Barzilay, AI Small Molecule Discovery and Synthesis

On this episode, I speak with Tim Guilliams and David Brown of Healx. Healx uses AI to repurpose existing drugs for rare diseases. They claim their approach can bring new treatments to patients 80% faster and 90% cheaper. On this episode, you’ll learn how rare diseases are surprisingly common, why drug repurposing holds promise to treat them, and how Healx uses AI to do it. And you will, I hope, be inspired by a powerful example of AI's potential in healthcare.

This episode is brought to you by BenchSci ( www.benchsci.com ). BenchSci uses artificial intelligence to reduce the time, uncertainty, and cost of scientific experiments. Use it to find research antibodies up to 24x faster than using PubMed or Google Scholar. Just enter a protein of interest and filter by technique, organism, tissue, or 15 other options. BenchSci returns only relevant published figures and products. It’s free for academic researchers. Learn more and sign up at www.benchsci.com .

Tim Guilliams and David Brown, Healx, AI for Rare Diseases

On this episode, I speak with John Cassidy, CEO of Cambridge Cancer Genomics ( www.ccg.ai ). CCG aims to transform oncology by combining liquid biopsy with genomics and artificial intelligence to predict disease progression and improve treatment. On this episode, you’ll learn about the challenges with chemotherapy that CCG is tackling, the role that liquid biopsy and artificial intelligence play in their solution, and how their approach could forever change the way we treat cancer.

This episode is brought to you by BenchSci ( www.benchsci.com ). BenchSci uses artificial intelligence to reduce the time, uncertainty, and cost of scientific experiments. Use it to find research antibodies up to 24x faster than using PubMed or Google Scholar. Just enter a protein of interest and filter by technique, organism, tissue, or 13 other options. BenchSci returns only relevant published figures and products. It’s free for academic researchers. Learn more and sign up at www.benchsci.com .

Nick Lynch of the Pistoia Alliance on AI as a Strategic Focus

Download our free app to listen on your phone